Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination with chemotherapy. In locally advanced NSCLC and in early resected stages, immunotherapy is also employed. Tumor PD-L1 expr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Santarpia, Mariacarmela, Aguilar, Andrés, Chaib, Imane, Cardona, Andrés Felipe, Fancelli, Sara, Laguia, Fernando, Bracht, Jillian Wilhelmina Paulina, Cao, Peng, Molina-Vila, Miguel Angel, Karachaliou, Niki, Rosell, Rafael
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352732/
https://ncbi.nlm.nih.gov/pubmed/32516941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061475
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares